Barclays’s Aspire Biopharma Warrant ASBPW Stock Holding History

Barclays’s Portfolio ASBPW Stock Details ASBPW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$145	Sell	8,750 -341,250	-98%	-$6.96K	﹤0.01%	4950
2025 Q4	$5.78K	Hold	350,000	–	–	﹤0.01%	4978
2025 Q3	$10.5K	Hold	350,000	–	–	﹤0.01%	5018
2025 Q2	$15.6K	Hold	350,000	–	–	﹤0.01%	4866
2025 Q1	$31.4K	Hold	350,000	–	–	﹤0.01%	4712
2024 Q4	$16.6K	Hold	350,000	–	–	﹤0.01%	4939
2024 Q3	$14.8K	Hold	350,000	–	–	﹤0.01%	4934
2024 Q2	$3.94M	Hold	350,000	–	–	﹤0.01%	1681
2024 Q1	$10.5K	Hold	350,000	–	–	﹤0.01%	4806
2023 Q4	$21K	Hold	350,000	–	–	﹤0.01%	4900
2023 Q3	$17.7K	Hold	350,000	–	–	﹤0.01%	4204
2023 Q2	$17.5K	Hold	350,000	–	–	﹤0.01%	4154
2023 Q1	$14.6K	Hold	350,000	–	–	﹤0.01%	4702
2022 Q4	$28K	Hold	350,000	–	–	﹤0.01%	4743
2022 Q3	$39K	Hold	350,000	–	–	﹤0.01%	3858
2022 Q2	$60K	Buy	+350,000	New	+$76.1K	﹤0.01%	3968

Other funds holding ASBPW

MTCM

Mint Tower Capital Management Amsterdam, Netherlands $1.12B AUM 18.84% 1-Year Est. Return

SCM

Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.91% 1-Year Est. Return

Sculptor Capital New York $9.61B AUM 27.5% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.25% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.21% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Barclays's ASBPW Position: Q1 2026 in Review

Barclays reduced its Aspire Biopharma Warrant (ASBPW) stake by 98% in Q1 2026, selling an estimated $6.96K and leaving 8,750 shares worth $145. The position accounts for ﹤0.01% of the portfolio, ranked #4950.

Barclays first reported a position in ASBPW in Q2 2022 and has held it in 16 quarters since. The position peaked at $3.94M in Q2 2024. 29 funds tracked by Wall St. Rank hold ASBPW as of Q1 2026.

Barclays held 8,750 shares of Aspire Biopharma Warrant worth $145 as of Q1 2026.
Barclays sold 341,250 Aspire Biopharma Warrant shares in Q1 2026, an estimated $6.96K.
Aspire Biopharma Warrant made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4950 holding.
Barclays first reported a position in Aspire Biopharma Warrant in Q2 2022 and has held it in 16 quarters since.
Barclays's Aspire Biopharma Warrant position peaked at $3.94M in Q2 2024.
29 funds tracked by Wall St. Rank held Aspire Biopharma Warrant as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.